A preclinical study demonstrated that neutralizing IL-1α reduced disease severity (IL-1α is a potent activator of fibroblast) in a mouse model of Crohn’s disease via modulation of the gut microbiome and correction of mucosal dysbiosis, suggesting potential therapeutic benefits [185]. This evidence concerns the gene IL1A and Crohn disease.